The paradigm of universal access to HIV-treatment and human rights violation: How do we treat HIV-positive people who use drugs?

Current HIV/AIDS Reports

Volumn 11, Issue 1, 2014, Pages 52-62

  Malta, Monica ^a   Ralil Da Costa, Michelle ^b   Bastos, Francisco Inácio ^c  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^c Oswaldo Cruz Foundation   (Brazil)

Author keywords

Drug use; HAART; Highly active antiretroviral therapy (HAART); HIV; HIV positive drug users; HIV positive people; HIV treatment; HIV treatment access; Human rights; People living with HIV (PLWHA); People who use drugs (PWUDs); PWUDs; Science of prevention; Treatment

Indexed keywords

ALCOHOLISM; ARTICLE; CAUCASIAN; CD4 LYMPHOCYTE COUNT; DEPRESSION; DRUG ABUSE; DRUG DEPENDENCE; EMERGENCY WARD; FEMININITY; HEALTH CARE ACCESS; HEALTH CARE DISPARITY; HEALTH INSURANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOUSING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN RIGHTS ABUSE; METHADONE TREATMENT; NAMED GROUPS OF PERSONS; NORTH AMERICA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PEOPLE WHO INJECT DRUG; PEOPLE WHO USE DRUG; PHYSICIAN; PREDICTOR VARIABLE; PREJUDICE; PRESCRIPTION; PRIMARY MEDICAL CARE; SOCIAL DISCRIMINATION; SOCIAL STIGMA; SYSTEMATIC REVIEW; THERAPEUTIC MISCONCEPTION; THERAPY DELAY; UKRAINE; WESTERN EUROPE; WORK EXPERIENCE;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HEALTH SERVICES ACCESSIBILITY; HIV INFECTIONS; HUMAN RIGHTS ABUSES; HUMANS; SOCIOECONOMIC FACTORS; SUBSTANCE-RELATED DISORDERS;

EID: 84896719007     PISSN: 15483568     EISSN: 15483576     Source Type: Journal    
DOI: 10.1007/s11904-013-0196-2     Document Type: Article

References (41)

1. Quinn TC. HIV epidemiology and the effects of antiviral therapy on long-term consequences. AIDS. 2008;22:S7-S12.
2. Broder S. The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res. 2010;85:1-18.
3. Achhra AC, Phanuphak P, Amin J. Long-term immunological outcomes in treated HIV-infected individuals in high-income and low-middle income countries. Curr Opin HIV AIDS. 2011;6:258-65.
4. Cohen J. Breakthrough of the year: HIV treatment as prevention. Science. 2011;334:1628.
5. CDC. Background brief on the prevention benefits of HIV treatment. http://www.cdc.gov/hiv/pdf/prevention-tap-benefits-of-HIV-treatement.pdf Accessed 14 Nov 2013.
6. Montaner JS, Wood E, Kerr T, Lima V, Barrios R, Shannon K, et al. Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes. J Acquir Immune Defic Syndr. 2010;55:S5-9.
7. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, McFarland W, et al.Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One. 2010;5:e11068.
8. Miller WC, Hoffman IF, Latkin CA, Strathdee SA, Shoptaw S. HIV antiretroviral prophylaxis for injecting drug users. Lancet. 2013;382:853.
9. Malta M, Strathdee SA, Magnanini MM, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction. 2008;103:1242-57. (Pubitemid 352009054)
10. Friedman SR,West BS, Pouget ER, Hall HI, Cantrell J, Tempalski B, et al. Metropolitan social environments and pre-HAART/HAART era changes in mortality rates (per 10,000 adult residents) among injection drug users living with AIDS. PLoS One. 2013;8:e57201.
11. Wood E, Hogg RS, Yip B, Dong WW, Wynhoven B, Mo T, et al. Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use. AIDS. 2005;19:1189-95. (Pubitemid 41059260)
12. Wood E, Montaner JS, Yip B, Tyndall MW, Schechter MT, O'Shaughnessy MV, et al. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ. 2003;169:656-61. (Pubitemid 37266973)
13. Wolfe D. Paradoxes in antiretroviral treatment for injecting drug users: access, adherence and structural barriers in Asia and the former Soviet Union. Int J Drug Policy. 2007;18:246-54. (Pubitemid 47135597)
14. Strathdee SA, Shoptaw S, Dyer TP, Quan VM, Aramrattana A, Substance Use Scientific Committee of the HIV Prevention Trials Network. Towards combination HIV prevention for injection drug users: addressing addictophobia, apathy and inattention. Curr Opin HIV AIDS. 2012;7:320-5.
15. Donoghoe MC, Bollerup AR, Lazarus JV, Nielsen S, Matic S. Access to highly active antiretroviral therapy (HAART) for injecting drug users in the WHO European Region 2002-2004. Int J Drug Policy. 2007;18:271-80. (Pubitemid 47126280)
16. Grigoryan A, Hall HI, Durant T, Wei X. Late HIV diagnosis and determinants of progression to AIDS or death after HIV diagnosis among injection drug users, 33 US States, 1996-2004. PLoS One. 2009;4:e4445.
17. McLellan AT, Lewis DC, O'Brien CP, Kleber HD. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA. 2000;284:1689-95.
18. Arria AM, McLellan AT. Evolution of concept, but not action, in addiction treatment. Subst Use Misuse. 2012;47:1041-8.
19. O'Shaughnessy MV, Hogg RS, Strathdee SA, Montaner JS. Deadly public policy: what the future could hold for the HIV epidemic among injection drug users in Vancouver. Curr HIV/AIDS Rep. 2012;9:394-400.
20. WHO. HIV/AIDS treatment and care for injecting drug users: Clinical protocol for theWHOEuropean region. Copenhagen: WHO Regional Office for Europe; 2006.
21. Human Rights Watch. Rhetoric and risk: Human rights abuses impeding Ukraine's fight against HIV/AIDS. New York: Human Rights Watch; 2006.
22. Taylor LE, Swan T, Matthews GV. Management of hepatitis C virus/HIV coinfection among people who use drugs in the era of direct-acting antiviral-based therapy. Clin Infect Dis. 2013;57:S118-24.
23. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
24. Westergaard RP, Hess T, Astemborski J, Mehta SH, Kirk GD. Longitudinal changes in engagement in care and viral suppression for HIV-infected injection drug users. AIDS. 2013;27:2559-66.
25. Celentano DD, Galai N, Sethi AK, Shah NG, Strathdee SA, Vlahov D, et al. Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users. AIDS. 2001;15:1707-15. (Pubitemid 32918126)
26. Rodríguez-Arenas MA, Jarrín I, del Amo J, Iribarren JA, Moreno S, Viciana P, et al. Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Res Hum Retroviruses. 2006;22:715-23. (Pubitemid 44734997)
27. Sohler NL, Wong MD, Cunningham WE, Cabral H, Drainoni ML, Cunningham CO. Type and pattern of illicit drug use and access to health care services for HIV-infected people. AIDS Patient Care STDS. 2007;21:S68-76.
28. Wood E, Kerr T, Zhang R, Guillemi S, Palepu A, Hogg RS, et al. Poor adherence to HIV monitoring and treatment guidelines for HIV-infected injection drug users. HIV Med. 2008;9(7):503-7.
29. Carrieri MP, Moatti JP, Vlahov D, Obadia Y, Reynaud-Maurupt C, Chesney M. Access to antiretroviral treatment among French HIV infected injection drug users: the influence of continued drug use. MANIF 2000 Study Group. J Epidemiol Community Health. 1999;53:4-8. (Pubitemid 29012343)
30. Strathdee SA, Palepu A, Cornelisse PG, Yip B, O'Shaughnessy MV, Montaner JS, et al. Barriers to use of free antiretroviral therapy in injection drug users. JAMA. 1998;280:547-9. (Pubitemid 28377675)
31. Fairbairn N, Milloy MJ, Zhang R, Lai C, Grafstein E, Kerr T, et al. Emergency department utilization among a cohort of HIV-positive injecting drug users in a Canadian setting. J Emerg Med. 2012;43:236-43.
32. Arasteh K, Des Jarlais DC. HIV testing and treatment among at-risk drinking injection drug users. J Int Assoc Physicians AIDS Care (Chic). 2009;8:196-201.
33. Uhlmann S,MilloyMJ, Kerr T, Zhang R, Guillemi S, Marsh D, et al. Methadone maintenance therapy promotes initiation of antiretroviral therapy among injection drug users. Addiction. 2010;105:907-13.
34. Tapp C, Milloy MJ, Kerr T, Zhang R, Guillemi S, Hogg RS, et al. Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare. BMC Infect Dis. 2011;11:86.
35. Gardner LI, Holmberg SD, Moore J, Arnsten JH, Mayer KH, Rompalo A, et al. Use of highly active antiretroviral therapy in HIV-infected women: impact of HIV specialist care. J Acquir Immune Defic Syndr. 2002;29:69-75. (Pubitemid 34094310)
36. Rompalo AM, Shah N, Mayer K, Schuman P, Klein RS, Smith DK, et al. Influence of injection drug use behavior on reported antiretroviral therapy use among women in the HIV Epidemiology Research study: on-site versus referral care. J Acquir Immune Defic Syndr. 2001;28:28-34. (Pubitemid 33104524)
37. Thorne C, Semenenko I, Malyuta R, Ukraine European Collaborative Study Group in EuroCoord. Prevention of mother-to-child transmission of human immunodeficiency virus among pregnant women using injecting drugs in Ukraine, 2000-10. Addiction. 2012;107:118-28.
38. Milloy MJ, Marshall BD, Kerr T, Buxton J, Rhodes T, Montaner J, et al. Social and structural factors associated with HIV disease progression among illicit drug users: a systematic review. AIDS. 2012;26:1049-63.
39. Degenhardt L, Mathers B, Vickerman P, Rhodes T, Latkin C, Hickman M. Prevention of HIV infection for people who inject drugs: why individual, structural, and combination approaches are needed. Lancet. 2010;376:285-301.
40. Wolfe D, Cohen J. Human rights and HIV prevention, treatment, and care for people who inject drugs: key principles and research needs. J Acquir Immune Defic Syndr. 2010;55 Suppl 1:S56-62.
41. Milloy MJ, Marshall BD, Kerr T, Buxton J, Rhodes T, Montaner J, et al. Social and structural factors associated with HIV disease progression among illicit drug users: a systematic review. AIDS. 2012;26(9):1049-63.